$1.59
-0.01[-0.63%]
At close: Apr 26
$1.59
0[0.00%]
After Hours: 4:00PM EDT
CytomX Therapeutics
(NASDAQ:CTMX)CytomX Therapeutics Stock (NASDAQ:CTMX), Analyst Ratings, Price Targets, Predictions
CytomX Therapeutics Inc has a consensus price target of $3.6, established from looking at the 25 latest analyst ratings. The last 3 analyst ratings were released from JP Morgan, BMO Capital, and Wedbush on April 22, 2024, March 12, 2024, and March 12, 2024. With an average price target of $2.08 between JP Morgan, BMO Capital, and Wedbush, there's an implied 31.03% upside for CytomX Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
BMO Capital
Wedbush
Mizuho
Cowen & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for CytomX Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/22/2024 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | — | JP Morgan | Anupam Rama | — | Upgrade | Underweight → Neutral | Get Alert |
| 03/12/2024 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 104.4% | BMO Capital | Etzer Darout | $3.3 → $3.25 | Maintains | Market Perform | Get Alert |
| 03/12/2024 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 88.68% | Wedbush | Robert Driscoll | → $3 | Reiterates | Neutral → Neutral | Get Alert |
| 11/09/2023 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 88.68% | Wedbush | Robert Driscoll | $2 → $3 | Maintains | Neutral | Get Alert |
| 11/08/2023 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 88.68% | Wedbush | Robert Driscoll | $2 → $3 | Upgrade | Neutral → Outperform | Get Alert |
| 08/09/2023 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 100.63% | BMO Capital | Etzer Darout | $3.15 → $3.19 | Maintains | Market Perform | Get Alert |
| 03/28/2023 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 25.79% | Mizuho | Mara Goldstein | $4 → $2 | Maintains | Neutral | Get Alert |
| 01/06/2023 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 101.26% | BMO Capital | Etzer Darout | $2.6 → $3.2 | Maintains | Market Perform | Get Alert |
| 11/14/2022 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 63.52% | BMO Capital | Etzer Darout | $3 → $2.6 | Downgrade | Outperform → Market Perform | Get Alert |
| 11/10/2022 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | — | JP Morgan | Anupam Rama | — | Downgrade | Overweight → Underweight | Get Alert |
| 07/11/2022 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | — | Cowen & Co. | Boris Peaker | — | Downgrade | Outperform → Market Perform | Get Alert |
| 07/11/2022 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | — | HC Wainwright & Co. | Mitchell Kapoor | — | Downgrade | Buy → Neutral | Get Alert |
| 07/07/2022 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 25.79% | Jefferies | Roger Song | $12 → $2 | Downgrade | Buy → Hold | Get Alert |
| 07/07/2022 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 88.68% | BMO Capital | Etzer Darout | $9 → $3 | Maintains | Outperform | Get Alert |
| 07/07/2022 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 403.14% | BTIG | Kaveri Pohlman | $16 → $8 | Maintains | Buy | Get Alert |
| 07/07/2022 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 25.79% | Wedbush | Robert Driscoll | $6 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 07/07/2022 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 120.13% | Barclays | Peter Lawson | $7 → $3.5 | Maintains | Overweight | Get Alert |
| 07/07/2022 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | 151.57% | Mizuho | Mara Goldstein | $16 → $4 | Downgrade | Buy → Neutral | Get Alert |
| 07/07/2022 | CTMX | Buy Now | CytomX Therapeutics | $1.59 | -5.66% | Piper Sandler | Joseph Catanzaro | $10 → $1.5 | Downgrade | Overweight → Neutral | Get Alert |
FAQ
What is the target price for CytomX Therapeutics (CTMX)?
The latest price target for CytomX Therapeutics (NASDAQ: CTMX) was reported by JP Morgan on April 22, 2024. The analyst firm set a price target for $0.00 expecting CTMX to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CytomX Therapeutics (CTMX)?
The latest analyst rating for CytomX Therapeutics (NASDAQ: CTMX) was provided by JP Morgan, and CytomX Therapeutics upgraded their neutral rating.
When was the last upgrade for CytomX Therapeutics (CTMX)?
The last upgrade for CytomX Therapeutics Inc happened on April 22, 2024 when JP Morgan raised their price target to N/A. JP Morgan previously had an underweight for CytomX Therapeutics Inc.
When was the last downgrade for CytomX Therapeutics (CTMX)?
The last downgrade for CytomX Therapeutics Inc happened on November 14, 2022 when BMO Capital changed their price target from $3 to $2.6 for CytomX Therapeutics Inc.
When is the next analyst rating going to be posted or updated for CytomX Therapeutics (CTMX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CytomX Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CytomX Therapeutics was filed on April 22, 2024 so you should expect the next rating to be made available sometime around April 22, 2025.
Is the Analyst Rating CytomX Therapeutics (CTMX) correct?
While ratings are subjective and will change, the latest CytomX Therapeutics (CTMX) rating was a upgraded with a price target of $0.00 to $0.00. The current price CytomX Therapeutics (CTMX) is trading at is $1.59, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.